Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications.
Pharmaceutics January 8, 2026 Shiryn D. Sukhram, Majandra Sanchez, Ayotunde Anidugbe et al.
Background: Depression and diabetic neuropathy (DN) commonly complicate diabetes and impair glycemic control and quality of life. Ketamine and its S-enantiomer, esketamine, provide rapid antidepressant and analgesic effects, yet diabetes-related pathophysiology and co-therapies may modify exposure, response, and safety. Methods: We conducted a scoping review following PRISMA-ScR....
DOI: 10.3390/pharmaceutics18010081 (opens in new tab)
Full text (opens in new tab)
Esketamine
Cyp2b6
Cyp3a4
Pk-pd
+5